NCT05271292 - Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions

Small Cell Lung CancerAdvanced Solid Malignant Tumor

Interventions

DRUG

Chiauranib

"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"

Trial Locations (11)

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

37203

RECRUITING

Sarah Cannon Research Center, Nashville

44718

RECRUITING

Gabrail Cancer Center Research, Canton

48201

RECRUITING

Karmanos Cancer Institute, Detroit

73104

RECRUITING

OU Health, Oklahoma City

77340

RECRUITING

North Houston Cancer Clinics, Huntsville

89119

RECRUITING

Comprehensive Cancer Centers of Nevada, Las Vegas

92024

RECRUITING

California Cancer Associates-Encintas, Encinitas

92835

RECRUITING

Providence/St. Joe Cancer Institute/Crosson Cancer Institute, Fullerton

02215

RECRUITING

Dana Farber Cancer Institue, Boston